Edition:
United States

Arena Pharmaceuticals Inc (ARNA.OQ)

ARNA.OQ on NASDAQ Stock Exchange Global Select Market

41.15USD
4:00pm EDT
Change (% chg)

$-0.37 (-0.89%)
Prev Close
$41.52
Open
$41.52
Day's High
$41.71
Day's Low
$40.55
Volume
65,210
Avg. Vol
188,983
52-wk High
$50.00
52-wk Low
$24.33

Chart for

About

Arena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the... (more)

Overall

Beta: 1.42
Market Cap(Mil.): $1,019.33
Shares Outstanding(Mil.): 39.22
Dividend: --
Yield (%): --

Financials

  ARNA.OQ Industry Sector
P/E (TTM): -- 85.92 33.73
EPS (TTM): -0.59 -- --
ROI: -13.16 0.63 14.31
ROE: -39.77 1.68 16.04

BRIEF-Arena Pharmaceuticals Reports Q1 Loss Per Share $0.80

* EXPECT TO INITIATE PHASE 3 STUDIES FOR RALINEPAG IN PULMONARY ARTERIAL HYPERTENSION IN SECOND HALF OF 2018

May 08 2018

BRIEF-Arena Pharmaceuticals To Release Q1 Financial Results And Provide Corporate Update On Tuesday, May 8

* ARENA PHARMACEUTICALS TO RELEASE FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDE CORPORATE UPDATE ON TUESDAY, MAY 8 Source text for Eikon: Further company coverage:

May 02 2018

Competitors

Earnings vs. Estimates